EVANGELISTI G.

Vasomotor symptoms (VMS) are common complaints in 80% of postmenopausal women, having a great impact on their global quality of life. Several therapeutic options are available for treating these patients. Hormonal replacement therapy is the current therapeutic standard for VMS, but it is associated with well-known potential risks. Fezolinetant...

No description

No description

No description

Tisotumab vedotin (TV) is a humanized antibody-drug conjugate (ADC) directed against tissue factor, a protein involved in signaling pathways related to angiogenesis, cell adhesion, motility and survival. It has been reported that tissue factor is aberrantly expressed by many types of solid tumors and it is associated with negative oncological...

No description

No description

No description

No description

Introduction: Uterine fibroids are the most common benign gynecological tumors affecting women of reproductive ages. Although surgery is the definitive treatment choice, several medical approaches have been investigated to control their symptoms. The main issue of currently employed drugs for uterine fibroids is the long-term safety and...

Introduction: Patients with high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and current chemotherapy regimens for treating advanced disease are far from satisfactory. Prexasertib (LY2606368) is a novel checkpoint kinase inhibitor (CHK) under investigation for the treatment of HGSOC. Data from a recent phase II trial showed...